AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Maxim Group Upgrades Coherus Oncology to Buy, Sets PT at $4
ByAinvest
Thursday, Sep 4, 2025 8:18 am ET1min read
Maxim Group Upgrades Coherus Oncology to Buy, Sets PT at $4
Maxim Group has upgraded its rating for Coherus Oncology (NASDAQ: CHRS) to "Buy" and set a price target (PT) of $4.00. The upgrade comes amidst positive developments for the company, including its participation in upcoming investor conferences and recent stock price appreciation [1].Coherus Oncology, a fully integrated commercial-stage innovative oncology company, announced its participation in three upcoming investor conferences in September and October 2025. The company will present at the Baird 2025 Global Healthcare Conference on September 9, the H.C. Wainwright Global Investment Conference on September 10, and the UBS Virtual Oncology Day on October 1, 2025. All presentations will be accessible through webcast links on the company's investor relations website, with replays available for 30 days [1].
The stock price of Coherus BioSciences has shown significant growth, rising by 5.88% on Wednesday, September 3, 2025, from $1.19 to $1.26. The stock has gained 43.13% since August 11, 2025, and has been on a strong upward trend, with positive technical signals from Moving Averages and MACD [2].
Maxim Group's upgrade reflects the company's strong fundamentals, including its approved next-generation PD-1 inhibitor, LOQTORZI® (toripalimab-tpzi), and a promising pipeline of proprietary candidates targeting various cancers. The company's strategy to grow sales of LOQTORZI and advance the development of new indications is expected to drive sales multiples and synergies from proprietary combinations [1].
Investors interested in Coherus Oncology's upcoming presentations or one-on-one meetings with management should contact their respective bank representatives. For more information about LOQTORZI, including the U.S. Prescribing Information and important safety information, visit the Coherus website [1].
References:
[1] https://www.stocktitan.net/news/CHRS/coherus-oncology-to-participate-in-upcoming-investor-tj4ax1swcqgp.html
[2] https://stockinvest.us/stock/CHRS
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet